Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Chief Medical Officer | June 01, 2026 | June 01, 2026 |
| TREVENA INCTRVN · Entity 85383 | Sr. VP,Clinical Dev. & CMO | March 02, 2017 | March 03, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MADRIGAL PHARMACEUTICALS, INC.
Report date June 01, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,033 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Sale · Disposed 1,042 · Balance 10,033 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026.
TREVENA INC
Report date March 02, 2017 · Filed March 03, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.13 · Expires 2027-03-02 | Direct | 91,000 |
Reported balance
After 2017-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-02 · Grant · Acquired 91,000 · Balance 91,000 F1: The option shall vest and become exercisable with respect to one-fourth of the total number of shares subject to the option on each of March 2, 2018, March 2, 2019, March 2, 2020 and March 2, 2021, subject to the reporting person's Continuous Service (as defined in the Trevena, Inc. 2013 Equity Incentive Plan, as amended) as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable with respect to one-fourth of the total number of shares subject to the option on each of March 2, 2018, March 2, 2019, March 2, 2020 and March 2, 2021, subject to the reporting person's Continuous Service (as defined in the Trevena, Inc. 2013 Equity Incentive Plan, as amended) as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 1, 2026 23:49 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,042 | $495.74 | $516,561.08 |
DisclosureSEC source: 0001628280-26-039653 · wk-form4_1780357747.xml · nonDerivative · entry 1 Soergel David · CIK 0001591475 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,033 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026. Read SEC document |
| May 18, 2026 Filed May 18, 2026 21:36 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 844 | $515.90 | $435,419.60 |
DisclosureSEC source: 0001628280-26-036078 · wk-form4_1779140170.xml · nonDerivative · entry 1 Soergel David · CIK 0001591475 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,075 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 22:55 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 5,467 | $0.00 Strike: $434.80 | $0.00 |
DisclosureSEC source: 0001628280-26-015722 · wk-form4_1772837756.xml · derivative · entry 2 Soergel David · CIK 0001591475 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,467 Underlying: Common Stock · 5,467 shares Expires 2036-03-04 F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 22:55 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 4,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015722 · wk-form4_1772837756.xml · nonDerivative · entry 1 Soergel David · CIK 0001591475 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,919 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| May 15, 2025 Filed May 16, 2025 22:23 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 12,839 | $0.00 Strike: $291.82 | $0.00 |
DisclosureSEC source: 0001628280-25-026346 · wk-form4_1747434224.xml · derivative · entry 2 Soergel David · CIK 0001591475 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,839 Underlying: Common Stock · 12,839 shares Expires 2035-05-15 F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (May 15, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| May 15, 2025 Filed May 16, 2025 22:23 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 7,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-026346 · wk-form4_1747434224.xml · nonDerivative · entry 1 Soergel David · CIK 0001591475 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,545 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of May 15, 2026, May 15, 2027, May 15, 2028 and May 15, 2029, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| March 02, 2017 Filed Mar 3, 2017 22:01 UTC | TREVENA INC TRVN · Entity 85383 | GrantEmployee Stock Option (Right to Buy) · Derivative | 91,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001209191-17-017703 · doc4.xml · derivative · entry 1 Soergel David · CIK 0001591475 · Sr. VP,Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,000 Underlying: Common Stock · 91,000 shares Expires 2027-03-02 F1 · derivative.exercise_date: The option shall vest and become exercisable with respect to one-fourth of the total number of shares subject to the option on each of March 2, 2018, March 2, 2019, March 2, 2020 and March 2, 2021, subject to the reporting person's Continuous Service (as defined in the Trevena, Inc. 2013 Equity Incentive Plan, as amended) as of each such vesting date. Read SEC document |
| January 06, 2017 Filed Jan 6, 2017 21:49 UTC | TREVENA INC TRVN · Entity 85383 | GrantEmployee Stock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001209191-17-002674 · doc4.xml · derivative · entry 1 Soergel David · CIK 0001591475 · Sr. VP,Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2027-01-06 F1 · derivative.exercise_date: The option shall vest and become exercisable with respect to one-fourth of the total number of shares subject to the option on each of January 6, 2018, January 6, 2019, January 6, 2020 and January 6, 2021, subject to the reporting person's Continuous Service (as defined in the Trevena, Inc. 2013 Equity Incentive Plan, as amended) as of each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.